# NCT03040999 (NCT03040999)

> Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03040999
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Head and Neck Neoplasms
- Interventions: Pembrolizumab; Placebo; Cisplatin; Accelerated Fractionation (AFX) Radiotherapy; Standard Fractionation (SFX) Radiotherapy
- Enrollment: 804
- Primary outcome: Event-free Survival (EFS)

## Commentary we found

- YouTube: 13
- Podcasts: 13
- X threads: 9

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct03040999

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03040999", "email": "<work email>"}; the inbox owner confirms by the emailed link.